SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-22-000018
Filing Date
2022-07-21
Accepted
2022-07-20 19:01:03
Documents
13
Period of Report
2022-07-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20220715.htm   iXBRL 8-K 44807
2 EX-10.1 exhibit101amendmentno2toar.htm EX-10.1 28416
  Complete submission text file 0001516551-22-000018.txt   209080

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20220715.xsd EX-101.SCH 1921
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20220715_lab.xml EX-101.LAB 22080
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20220715_pre.xml EX-101.PRE 11526
7 EXTRACTED XBRL INSTANCE DOCUMENT skye-20220715_htm.xml XML 10674
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 221095340
SIC: 2834 Pharmaceutical Preparations